We are happy to announce that Centro Sperimentale del Latte’s Z2 has been authorized by AIFA to produce pharmaceutical-grade freeze-dried cultures.
In a nutshell, pharmaceutical-grade products require high-standard quality systems to be in place, as well as structures, equipment, and processes that guarantee high and consistent quality productions.
Above all, this achievement was the result of hard work and a great team effort by many groups within our company:
- The Quality Assurance team managed all regulatory aspects, including application, preparation, and submission of GMP procedures, equipment qualification, process validation, etc., interface with the authorities, and overall monitoring of the project.
- The Production team was in charge of operations such as preparation and collection of plant documentation, executing tests, interface with suppliers, and drafting of relevant procedures, among others.
- The Quality Control team provided its support in the development of the quality control plan, executing the sampling and analyses necessary for qualifications and validations, etc.
This certification marks another great step on the path to growth that Centro Sperimentale del Latte started some years ago, with the objective to deliver high-quality probiotic cultures and to be a player in the pharmaceutical business worldwide.
Latest News
An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.
The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy
“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
Nous sommes fiers de présenter la cinquième édition de notre rapport de durabilité, une occasion de réfléchir sur les réalisations atteintes et les défis à venir…
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici, Sacco
Indianapolis, Ind., and Yeerongpilly, Queensland, Australia, March 13, 2024 – List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce
Sacco System est le pôle biotechnologique international dédié à l’industrie alimentaire, nutraceutique pharmaceutique, basé sur la tradition…
We are proud to announce that Sacco System has made a significant donation in support of Action4Diabetes (A4D), mission—a UK-based charity committed to ensuring free access to crucial medical supplies,
This year too, SACCO SYSTEM proudly participates in the Deploy Your Talents (DYT) project, promoted by the Fondazione Sodalitas, with the patronage of the Municipality of Milan and in collaboration